Kidney Function Change and All-Cause Mortality in Denosumab Users with and without Chronic Kidney Disease
Denosumab is approved for osteoporosis treatment in subjects with and without chronic kidney disease (CKD). Confirmation is required for its safety, treatment adherence, renal function effect, and mortality in patients with CKD. A retrospective cohort study was conducted to compare new users of deno...
Main Authors: | Ping-Hsun Wu, Ming-Yen Lin, Teng-Hui Huang, Tien-Ching Lee, Sung-Yen Lin, Chung-Hwan Chen, Mei-Chuan Kuo, Yi-Wen Chiu, Jer-Ming Chang, Shang-Jyh Hwang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/12/2/185 |
Similar Items
-
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
by: Chaiho Jeong, et al.
Published: (2023-04-01) -
Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study
by: Yusuke Kunimoto, et al.
Published: (2023-12-01) -
Impact of the COVID-19 Pandemic on Adherence to Denosumab Therapy: A Single Center Study
by: Kazuyoshi Kobayashi, et al.
Published: (2023-10-01) -
Comparative Adverse Kidney Outcomes in Women Receiving Raloxifene and Denosumab in a Real-World Setting
by: Hsin-Wei Chen, et al.
Published: (2022-06-01) -
Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling
by: Lei Shangguan, et al.
Published: (2024-12-01)